Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefi

First Page		Document Content
Date: 2015-03-12 23:53:04 Organ failure Immunosuppressants Eculizumab Kidney diseases Hemolytic-uremic syndrome Chronic kidney disease Dialysis Pharmaceutical Benefits Scheme Kidney transplantation Medicine Health Nephrology		Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefi Add to Reading List Source URL: pbs.gov.au Download Document from Source Website File Size: 48,27 KB Share Document on Facebook

	My Health Record system Application to register for a My Health Record Purpose of this form DocID: 1q840 - View Document
	Key findings and recommendations DocID: 1q0IM - View Document
	DOHA_stacked_eHealth_inline DocID: 1oMB9 - View Document
	Save On Health Care    DocID: 1ndVH - View Document
	April 21, 2015 The Honorable Rob Bonta Chair, Assembly Health Committee State Capitol, Room 6005 Sacramento, CARe: SUPPORT the Pharmaceutical Cost Transparency Act ofAB 463) DocID: 19Z75 - View Document